HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Permission Requests Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Hausen, B. Articles by Haverich, A. Search for Related Content PubMed PubMed Citation Articles by Hausen, B. Articles by Haverich, A.

European Journal of Cardio-Thoracic Surgery, Vol 7, 257-261, Copyright © 1993 by European Association for Cardio-thoracic Surgery

ARTICLES

The impact of early postoperative cyclosporine serum levels on the incidence of cardiac allograft rejection

B Hausen, S Demertzis, HJ Schafers, TH Wahlers, I Wagenbreth and A Haverich
Department of Thoracic and Cardiovascular Surgery, Hannover Medical School, Germany.

The introduction of cyclosporine A (CyA) into the immunosuppressive therapy has significantly improved the results of heart transplantation (HTX). Its nephrotoxicity and hepatotoxicity, however, often limit the perioperative and postoperative use of this drug. The purpose of this retrospective study was to evaluate the effect of early postoperative CyA blood levels on the incidence of early as well as late cardiac rejection and patients' survival. Between October 1985 and June 1991, HTX was performed in 311 patients. Standard immunosuppression consisted of azathioprine (1-2 mg/kg), prednisolone (0.5 to 0.1 mg/kg) and CyA. Rabbit-antithymocyte-globulin (RATG - 1.5 mg/kg) was administered for the first 4 days postoperatively. Moderate rejection was treated with 3 x 500 mg methylprednisolone, severe rejection with RATG (1.5 mg/kg three times a day). Patients were excluded from this study because of a positive cross-matching, early death unrelated to rejection or alternate forms of immunosuppression (n = 111). Follow-up was complete in 200 patients (mean age 44 +/- 11; 18 female, 182 male; 204,233 patient days) with a total of 5380 biopsies. The cohort was divided into group I (no CyA for day 0 to 2; n = 108) and group II (CyA during day 0 to 2; n = 92) according to the onset of CyA therapy. In 101 patients (group A) the mean CyA blood level was less than 150 ng/ml from day 0 to 14 and in 99 patients more than 150 ng/ml (group B).(ABSTRACT TRUNCATED AT 250 WORDS)

This article has been cited by other articles:

				X. M. Mueller Drug immunosuppression therapy for adult heart transplantation. Part 2: clinical applications and results Ann. Thorac. Surg., January 1, 2004; 77(1): 363 - 371. [Abstract] [Full Text] [PDF]

				H. P. B.-L. Rocca, G. Sutsch, J. Schneider, F. Follath, and W. Kiowski Natural Course of Moderate Cardiac Allograft Rejection (International Society for Heart Transplantation Grade 2) Early and Late After Transplantation Circulation, September 15, 1996; 94(6): 1334 - 1338. [Abstract] [Full Text]

				B. Hausen, J. M. Albes, R. Rohde, S. Demertzis, A. Mugge, and H.-J. Schafers Tricuspid Valve Regurgitation Attributable to Endomyocardial Biopsies and Rejection in Heart Transplantation Ann. Thorac. Surg., May 1, 1995; 59(5): 1134 - 1140. [Abstract] [Full Text]